Marine Pharmaceutical Market Size to Hit USD 10.26 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Marine Pharmaceutical Market

5.1. COVID-19 Landscape: Marine Pharmaceutical Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Marine Pharmaceutical Market, By Source Organism

8.1. Marine Pharmaceutical Market Revenue and Volume, by Source Organism

8.1.1. Marine Microorganisms

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Marine Invertebrates

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Marine Algae

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Marine Vertebrates

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Others (Sea Cucumbers, Deep-sea extremophiles)

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Marine Pharmaceutical Market, By Compound Type

9.1. Marine Pharmaceutical Market Revenue and Volume, by Compound Type

9.1.1. Polyketides

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Peptides

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Alkaloids

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Terpenoids

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Macrolides

9.1.5.1. Market Revenue and Volume Forecast

9.1.6. Fatty Acids

9.1.6.1. Market Revenue and Volume Forecast

9.1.7. Others (Saponins, Phenolics, Glycosides)

9.1.7.1. Market Revenue and Volume Forecast

Chapter 10. Global Marine Pharmaceutical Market, By Therapeutic Area

10.1. Marine Pharmaceutical Market Revenue and Volume, by Therapeutic Area

10.1.1. Oncology

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Infectious Diseases

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Neurology

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Cardiovascular Diseases

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Inflammatory & Autoimmune Diseases

10.1.5.1. Market Revenue and Volume Forecast

10.1.6. Pain Management

10.1.6.1. Market Revenue and Volume Forecast

10.1.7. Others (Dermatological, Endocrine)

10.1.7.1. Market Revenue and Volume Forecast

Chapter 11. Global Marine Pharmaceutical Market, By Product Type

11.1. Marine Pharmaceutical Market Revenue and Volume, by Product Type

11.1.1. Approved Drugs

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Marine-Derived Nutraceuticals

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Marine Peptide APIs (Bulk Supply)

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global Marine Pharmaceutical Market, By Development Stage

12.1. Marine Pharmaceutical Market Revenue and Volume, by Development Stage

12.1.1. Discovery

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Preclinical

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Clinical Trials

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Commercialized

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Marine Pharmaceutical Market, By End Use

13.1. Marine Pharmaceutical Market Revenue and Volume, by End Use

13.1.1. Pharmaceutical Companies

13.1.1.1. Market Revenue and Volume Forecast

13.1.2. Biotechnology Companies

13.1.2.1. Market Revenue and Volume Forecast

13.1.3. Academic & Research Institutes

13.1.3.1. Market Revenue and Volume Forecast

13.1.3. Contract Research Organizations (CROs)

13.1.3.1. Market Revenue and Volume Forecast

13.1.3. Marine Biotech Startups

13.1.3.1. Market Revenue and Volume Forecast

Chapter 14. Global Marine Pharmaceutical Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Volume Forecast, by Source Organism

14.1.2. Market Revenue and Volume Forecast, by Compound Type

14.1.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.1.4. Market Revenue and Volume Forecast, by Product Type

14.1.5. Market Revenue and Volume Forecast, by Development Stage

14.1.6. Market Revenue and Volume Forecast, by End Use

14.1.7. U.S.

14.1.7.1. Market Revenue and Volume Forecast, by Source Organism

14.1.7.2. Market Revenue and Volume Forecast, by Compound Type

14.1.7.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.1.7.4. Market Revenue and Volume Forecast, by Product Type

14.1.8. Market Revenue and Volume Forecast, by Development Stage

14.1.8.1. Market Revenue and Volume Forecast, by End Use

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Volume Forecast, by Source Organism

14.1.9.2. Market Revenue and Volume Forecast, by Compound Type

14.1.9.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.1.9.4. Market Revenue and Volume Forecast, by Product Type

14.1.10. Market Revenue and Volume Forecast, by Development Stage

14.1.11. Market Revenue and Volume Forecast, by End Use

14.2. Europe

14.2.1. Market Revenue and Volume Forecast, by Source Organism

14.2.2. Market Revenue and Volume Forecast, by Compound Type

14.2.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.2.4. Market Revenue and Volume Forecast, by Product Type

14.2.5. Market Revenue and Volume Forecast, by Development Stage

14.2.6. Market Revenue and Volume Forecast, by End Use

14.2.8. UK

14.2.8.1. Market Revenue and Volume Forecast, by Source Organism

14.2.8.2. Market Revenue and Volume Forecast, by Compound Type

14.2.8.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.2.9. Market Revenue and Volume Forecast, by Product Type

14.2.10. Market Revenue and Volume Forecast, by Development Stage

14.2.10.1. Market Revenue and Volume Forecast, by End Use

14.2.11. Germany

14.2.11.1. Market Revenue and Volume Forecast, by Source Organism

14.2.11.2. Market Revenue and Volume Forecast, by Compound Type

14.2.11.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.2.12. Market Revenue and Volume Forecast, by Product Type

14.2.13. Market Revenue and Volume Forecast, by Development Stage

14.2.14. Market Revenue and Volume Forecast, by End Use

14.2.15. France

14.2.15.1. Market Revenue and Volume Forecast, by Source Organism

14.2.15.2. Market Revenue and Volume Forecast, by Compound Type

14.2.15.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.2.15.4. Market Revenue and Volume Forecast, by Product Type

14.2.16. Market Revenue and Volume Forecast, by Development Stage

14.2.16.1. Market Revenue and Volume Forecast, by End Use

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Volume Forecast, by Source Organism

14.2.17.2. Market Revenue and Volume Forecast, by Compound Type

14.2.17.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.2.17.4. Market Revenue and Volume Forecast, by Product Type

14.2.18. Market Revenue and Volume Forecast, by Development Stage

14.2.18.1. Market Revenue and Volume Forecast, by End Use

14.3. APAC

14.3.1. Market Revenue and Volume Forecast, by Source Organism

14.3.2. Market Revenue and Volume Forecast, by Compound Type

14.3.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.3.4. Market Revenue and Volume Forecast, by Product Type

14.3.5. Market Revenue and Volume Forecast, by Development Stage

14.3.6. Market Revenue and Volume Forecast, by End Use

14.3.7. India

14.3.7.1. Market Revenue and Volume Forecast, by Source Organism

14.3.7.2. Market Revenue and Volume Forecast, by Compound Type

14.3.7.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.3.7.4. Market Revenue and Volume Forecast, by Product Type

14.3.8. Market Revenue and Volume Forecast, by Development Stage

14.3.9. Market Revenue and Volume Forecast, by End Use

14.3.10. China

14.3.10.1. Market Revenue and Volume Forecast, by Source Organism

14.3.10.2. Market Revenue and Volume Forecast, by Compound Type

14.3.10.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.3.10.4. Market Revenue and Volume Forecast, by Product Type

14.3.11. Market Revenue and Volume Forecast, by Development Stage

14.3.11.1. Market Revenue and Volume Forecast, by End Use

14.3.12. Japan

14.3.12.1. Market Revenue and Volume Forecast, by Source Organism

14.3.12.2. Market Revenue and Volume Forecast, by Compound Type

14.3.12.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.3.12.4. Market Revenue and Volume Forecast, by Product Type

14.3.12.5. Market Revenue and Volume Forecast, by Development Stage

14.3.12.6. Market Revenue and Volume Forecast, by End Use

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Volume Forecast, by Source Organism

14.3.13.2. Market Revenue and Volume Forecast, by Compound Type

14.3.13.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.3.13.4. Market Revenue and Volume Forecast, by Product Type

14.3.13.5. Market Revenue and Volume Forecast, by Development Stage

14.3.13.6. Market Revenue and Volume Forecast, by End Use

14.4. MEA

14.4.1. Market Revenue and Volume Forecast, by Source Organism

14.4.2. Market Revenue and Volume Forecast, by Compound Type

14.4.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.4.4. Market Revenue and Volume Forecast, by Product Type

14.4.5. Market Revenue and Volume Forecast, by Development Stage

14.4.6. Market Revenue and Volume Forecast, by End Use

14.4.7. GCC

14.4.7.1. Market Revenue and Volume Forecast, by Source Organism

14.4.7.2. Market Revenue and Volume Forecast, by Compound Type

14.4.7.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.4.7.4. Market Revenue and Volume Forecast, by Product Type

14.4.8. Market Revenue and Volume Forecast, by Development Stage

14.4.9. Market Revenue and Volume Forecast, by End Use

14.4.10. North Africa

14.4.10.1. Market Revenue and Volume Forecast, by Source Organism

14.4.10.2. Market Revenue and Volume Forecast, by Compound Type

14.4.10.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.4.10.4. Market Revenue and Volume Forecast, by Product Type

14.4.11. Market Revenue and Volume Forecast, by Development Stage

14.4.12. Market Revenue and Volume Forecast, by End Use

14.4.13. South Africa

14.4.13.1. Market Revenue and Volume Forecast, by Source Organism

14.4.13.2. Market Revenue and Volume Forecast, by Compound Type

14.4.13.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.4.13.4. Market Revenue and Volume Forecast, by Product Type

14.4.13.5. Market Revenue and Volume Forecast, by Development Stage

14.4.13.6. Market Revenue and Volume Forecast, by End Use

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Volume Forecast, by Source Organism

14.4.14.2. Market Revenue and Volume Forecast, by Compound Type

14.4.14.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.4.14.4. Market Revenue and Volume Forecast, by Product Type

14.4.14.5. Market Revenue and Volume Forecast, by Development Stage

14.4.14.6. Market Revenue and Volume Forecast, by End Use

14.5. Latin America

14.5.1. Market Revenue and Volume Forecast, by Source Organism

14.5.2. Market Revenue and Volume Forecast, by Compound Type

14.5.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.5.4. Market Revenue and Volume Forecast, by Product Type

14.5.5. Market Revenue and Volume Forecast, by Development Stage

14.5.6. Market Revenue and Volume Forecast, by End Use

14.5.7. Brazil

14.5.7.1. Market Revenue and Volume Forecast, by Source Organism

14.5.7.2. Market Revenue and Volume Forecast, by Compound Type

14.5.7.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.5.7.4. Market Revenue and Volume Forecast, by Product Type

14.5.8. Market Revenue and Volume Forecast, by Development Stage

14.5.8.1. Market Revenue and Volume Forecast, by End Use

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Volume Forecast, by Source Organism

14.5.9.2. Market Revenue and Volume Forecast, by Compound Type

14.5.9.3. Market Revenue and Volume Forecast, by Therapeutic Area

14.5.9.4. Market Revenue and Volume Forecast, by Product Type

14.5.9.5. Market Revenue and Volume Forecast, by Development Stage

14.5.9.6. Market Revenue and Volume Forecast, by End Use

Chapter 15. Company Profiles

15.1. Bristol Myers Squibb (linked with trabectedin distribution)

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Abyss Ingredients

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Sirenas Marine Discovery

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. GlycoMar Ltd.

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Chugai Pharmaceutical Co., Ltd.

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Okinawa Institute of Science and Technology (OIST)

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Neurochem Inc.

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Sinclair Pharmaceuticals

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Biotika (Slovakia)

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Tethys Research LLC

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The marine pharmaceutical market size is expected to increase from USD 6.15 billion in 2024 to USD 10.26 billion by 2034.

The marine pharmaceutical market is expected to grow at a compound annual growth rate (CAGR) of around 5.25% from 2025 to 2034.

The major players in the marine pharmaceutical market include PharmaMar S.A., Nereus Pharmaceuticals, Bristol Myers Squibb, Innate Pharma, Esperance Pharmaceuticals, Abyss Ingredients, SeaPharm Inc., Marinomed Biotech AG, Biomar Microbial Technologies, Sirenas Marine Discovery, GlycoMar Ltd., Marine Biotech Co., Ltd. (China), Chugai Pharmaceutical Co., Ltd., Okinawa Institute of Science and Technology (OIST), OceanX Biotech, Aker BioMarine, Neurochem Inc., Sinclair Pharmaceuticals, Biotika (Slovakia), and Tethys Research LLC.

The driving factors of the marine pharmaceutical market are the tools such as AI, metagenomics, and high-throughput screening are accelerating the identification and development of marine compounds.

North America region will lead the global marine pharmaceutical market during the forecast period 2025 to 2034.